Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.53 |
| ▸ | TUBB | P07437 | 5/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21921357 | 0.89 | CYP3A4 (0.58) | CYP3A4KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL10757240 | 0.86 | TUBB4A (0.50) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL377390 | 0.85 | SLC22A6 (0.55) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3296867 | 0.85 | HPGD (0.58) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL153056 | 0.85 | CA12 (0.59) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10796876 | 0.84 | ELANE (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28945286 | 0.84 | TUBB4A (0.51) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2729632 | 0.83 | TSHR (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15495759 | 0.83 | TUBB4A (0.47) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10798476 | 0.83 | TUBB1 (0.49) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265585-B2 | Golf ball | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
| US-10195489-B2 | Golf ball | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10188910-B2 | Golf ball | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2019-01-29 | — | — | US | disclosed |
| US-9975007-B2 | Golf ball | DUNLOP SPORTS CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20180126226-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180056137-A1 | GOLF BALL | DUNLOP SPORTS CO. LTD. (JP) | 2018-03-01 | — | — | US | disclosed |
| US-9873022-B2 | Golf ball | DUNLOP SPORTS CO. LTD. (JP) | 2018-01-23 | — | — | US | disclosed |
| EP-2610291-B1 | GOLF BALL | DUNLOP SPORTS CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-2668978-B1 | Golf ball | DUNLOP SPORTS CO LTD (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-9751272-B2 | Method for manufacturing a golf ball | DUNLOP SPORTS CO. LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| WO-2007146323-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| US-5008449-A | Method of synthesis of hydroxy-substituted-4-alkoxyphenylacetic acids | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1991-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | CYP3A4 2164/4885TUBB4A 2484/4885TUBB 2480/4885 |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K6 | CYP3A4 2163/4885TUBB4A 2504/4885TUBB 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.